ALX ONCOLOGY HOLDINGS INC (ALXO) Stock News
NASDAQ:ALXO - Nasdaq - US00166B1052 - Common Stock - Currency: USD
ALXO Latest News, Press Releases and Analysis
Which stocks are gapping on Thursday?
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor response...
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings, Inc. (“ALX Oncology” or the “Company”), (Nasdaq: ALXO), a...
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium
/PRNewswire/ -- USA News Group News Commentary – Big developments are expected this week at the 2025 ASCO Gastrointestinal Cancers Symposium, running January...
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors
Mr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and corporate...
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review updated data from trial evaluating CD47-blocker evorpacept in HER2-positive gastric cancer ...
ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a...
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
Webcast on December 17 at 8:00 AM EST to feature ALX Oncology leadership and study principal investigator Alberto J. Montero, MD, MBA SOUTH SAN FRANCISCO,...
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
Data from Phase 1b/2 clinical trial to be presented at 2024 San Antonio Breast Cancer Symposium (SABCS) show encouraging clinical activity in patients with...
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development...
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
ALX Oncology Announces November Investor Conference Participation
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination...
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal antibody in patients with multiple myeloma
Noteworthy Friday Option Activity: ETSY, ASTS, ALXO
ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q2 2024
ALXO stock results show that ALX Oncology Holdings beat analyst estimates for earnings per share the second quarter of 2024.
ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ALX Oncology Holdings (NASDAQ:ALXO) just reported results for the second quarte...
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
- Dr. Sandler brings more than 30 years of experience and leadership in oncology and drug development - - Jaume Pons, Ph.D., and Sophia Randolph, M.D.,...
Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
On Wednesday, ALX Oncology Holdings Inc. (NASDAQ:ALXO) released topline data from its Phase 2 ASPEN-06 clinical trial. ASPEN-06 is evaluating evorpacept in combination with trastuzumab, Cyramza (ramucirumab), and paclitaxel (collectively, TRP) against TRP alone for HER2-positive gastric/GEJ cancer, where all patients had received an anti-HER2 agent in prior lines of therapy. The ASPEN-06 study is testing a new treatment combination for advanced stomach and gastroesophageal cancer in patients who
ALX Oncology Holdings Enters Oversold Territory (ALXO)
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
Evorpacept is the first CD47 blocker to show durable clinical benefit and a well-tolerated safety profile in a prospective randomized trial ...